Related Experiment Video
Updated: Aug 15, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Remission of hormone-refractory prostate cancer attributed to Essiac
Wigdan Al-Sukhni1, Ami Grunbaum, Neil Fleshner
1Division of Urology, The Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
The Canadian Journal of Urology
|November 9, 2005
Abstract:
Essiac is a popular complementary and alternative medicine (CAM) that is utilized by many cancer patients in North America. Much anecdotal reporting exists about its cancer-fighting qualities, but so far no clinical trials have been preformed to validate those claims. We describe here the case of a 64-year-old man whose hormone-refractory prostate cancer responded well to Essiac tea.